Komori
Pharma Foods International (2929) · PolicyAdvanced

Strengthening Governance Through a Strong Focus on Transparency and Compliance

First written in FY2019. 4 of 5 entries say "Advanced", first in FY2021. Latest entry: FY2026.

5entries
8years
1from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2019AdvancedFY2021 – FY20262019: 12020: 020202021: 120212022: 120222023: 020232024: 020242025: 020252026: 22026
Same theme, other companies
Integrated Strengthening of Internal Controls, Corporate Governance and ComplianceA theme 354 companies write about · 2 as a headwind · 353 as a tailwind

73 other companies' latest entry also says "Advanced".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 200 companies compared. The sentences above are computed from all 200.Comparing 200 of the theme's 355 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「As of the filing date, 23 October 2026, the Board of Directors comprises 10 directors, including 4 outside directors.」

    In addition to its policy of strengthening governance, the Company has disclosed specific information on its structure of 10 directors, including 4 outside directors, and the operations of its Nominating and Compensation Committee and Risk and Compliance Committee.
  2. 2026-10-02AdvancedGeneral Meetings of Shareholders

    「We position compliance with laws and regulations as one of the most important issues in conducting business. To establish a compliance framework and improve its effectiveness, we will establish a risk and compliance committee chaired by an independent outside director.」

    Compliance was identified as an important issue, with specific operations described for the internal control and oversight framework, including a committee chaired by an independent outside director, reporting hotlines, internal audits and reporting to Audit & Supervisory Board members.
  3. FY2022AdvancedAnnual report

    「d. Nomination and Compensation Committee To strengthen the Board of Directors’ oversight function and accountability and enhance the quality of deliberations, the Company has established a Nomination and Compensation Committee as an advisory body to the Board of Directors. More than half of its members are independent outside directors.」

    In addition to emphasizing transparency and compliance, the Company discloses specific oversight and management structures, including the Nomination and Compensation Committee, Risk and Compliance Committee, and internal audit function.
  4. FY2021AdvancedAnnual report

    「At a meeting of the Board of Directors held on 15 February 2021, the Company resolved its policy for determining the details of individual directors’ compensation and other benefits, and revised that policy on 21 September of the same year.」

    Following consultation with and recommendations from the Nomination and Compensation Committee, the Company resolved and revised its directors’ compensation policy and established specific governance oversight and accountability mechanisms, including outside directors.
  5. FY2019First statedAnnual report

    「We will thoroughly improve management transparency and emphasize compliance, work to strengthen our corporate governance framework, and strive to become a company that creates value for all stakeholders, including shareholders, customers, local communities and employees.」

    The objectives of strengthening governance are to enhance management transparency, compliance, and value creation for all stakeholders.
Moved together

"Advertising Investment and Product Brand Expansion in Mail-Order Sales" moved the same way as this thread, in the same document, in 3 of its 5 moves.

333333★123456
  1. ★This thread
  2. 1Advertising Investment and Product Brand Expansion in Mail-Order Sales3×
  3. 2Development of antibody therapeutics using proprietary chicken antibody technology3×
  4. 3Research and development expenditures3×
  5. 4Raising Working Capital through Borrowings3×
  6. 5Expanding Enterprise Value Through the Active Pursuit of M&A3×
  7. 6Expansion of Strategic Patent Applications and Registrations for Research Results3×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Pharma Foods International yet. It last moved in the General Meetings of Shareholders of 2026-10-02: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.